Provention Bio (PRVB) Releases Earnings Results

Provention Bio (NASDAQ:PRVB) issued its earnings results on Thursday. The company reported ($0.17) earnings per share (EPS) for the quarter, Morningstar.com reports.

Shares of PRVB traded down $0.02 during mid-day trading on Friday, reaching $3.16. The company had a trading volume of 21,053 shares, compared to its average volume of 51,935. Provention Bio has a twelve month low of $2.52 and a twelve month high of $8.00.

A hedge fund recently bought a new stake in Provention Bio stock. Dean Capital Investments Management LLC bought a new position in Provention Bio Inc (NASDAQ:PRVB) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 40,950 shares of the company’s stock, valued at approximately $164,000. Dean Capital Investments Management LLC owned approximately 0.12% of Provention Bio at the end of the most recent quarter.

COPYRIGHT VIOLATION NOTICE: “Provention Bio (PRVB) Releases Earnings Results” was originally published by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/11/10/provention-bio-prvb-releases-earnings-results.html.

About Provention Bio

Provention Bio, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-6527, oral CSF-1R inhibitor, which is in Phase 2a clinical trial for the treatment of Crohn's disease; PRV-300, anti-TLR3 mAb, which is in Phase 1b clinical trial for the treatment of ulcerative colitis; PRV-3279 for the treatment of lupus; and PRV-101, a multivalent coxsackie virus vaccine for the prevention of acute Coxsackie Virus B Vaccine and the prevention of the onset of T1D.

Further Reading: What are no-load funds?

Receive News & Ratings for Provention Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Provention Bio and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply